LIVONIA, Mich.– Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading operations, development, and global growth of the company and its d-Nav® Insulin Management Program.
Lawrence brings three decades of medical technology leadership to his new role at Hygieia, including significant experience bringing products to market, restructuring and guiding companies through mergers and acquisitions, building global sales teams, raising venture capital, and overseeing operations.
Lawrence is an experienced CEO who previously led three companies including CeQur, a company that makes insulin patch pumps to treat type 2 diabetes. Previously, he led the diabetes business at Becton Dickinson (now Embecta), the world’s leading manufacturer of insulin syringes and pen needles.
“Doug has the perfect combination of experience and skill to shepherd Hygieia’s expansion in the United States and around the world,” said Eran Bashan, Ph.D., Hygieia co-founder and chairman of the board. “Now, with Doug serving as CEO, we will work together to build the nation’s leading network of diabetes clinics. The world of healthcare delivery is rapidly changing, and Doug’s leadership will allow us to accelerate our go-to-market plan. We are looking forward to partnering with others to simplify insulin therapy and improve outcomes.”
“Diabetes is a global epidemic imposing tremendous costs on patients and health systems. Late stage, insulin-dependent diabetes can be incredibly challenging for patients and their medical partners to manage effectively. I’m thrilled to join this talented, passionate team whose proven, FDA-cleared d-Nav Technology is poised to transform the safety and efficacy of insulin therapy and, in many cases, lower the overall cost of diabetes management,” said Lawrence.
“Hygieia delivers a scalable, autonomous digital therapy that enables physicians to automatically deliver individualized and daily customized insulin therapy for each of their patients with type 2 diabetes,” said Lawrence.
